[1]李　兵　张溢华　黄　平　陈立朝　贺绪智　梁　鸿　徐伦山　许民辉.垂体腺瘤术后复发的危险因素分析[J].中国临床神经外科杂志,2020,(07):436-438.[doi:10.13798/j.issn.1009-153X.2020.07.007]
　LI Bing,ZHANG Yi-hua,HUANG Ping,et al.Analysis of risk factors for postoperative recurrence of pituitary adenomas[J].,2020,(07):436-438.[doi:10.13798/j.issn.1009-153X.2020.07.007]
点击复制

垂体腺瘤术后复发的危险因素分析()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年07期
页码:
436-438
栏目:
论著
出版日期:
2020-07-25

文章信息/Info

Title:
Analysis of risk factors for postoperative recurrence of pituitary adenomas
文章编号:
1009-153X（2020）07-0436-03
作者:
李　兵　张溢华　黄　平　陈立朝　贺绪智　梁　鸿　徐伦山　许民辉
400042 重庆，中国人民解放军陆军军医大学大坪医院神经外科（李　兵、张溢华、黄　平、陈立朝、贺绪智、梁　鸿、徐伦山、许民辉）
Author(s):
LI Bing;  ZHANG Yi-hua;  HUANG Ping;  CHEN Li-zhao;  HE Xu-zhi;  LIANG Hong;  XU Lun-shan;  XU Min-hui.
Department of Neurosurgery, Daping Hospital, PLA Army Medical University, Chongqing 400042, China
关键词:
垂体腺瘤; 术后复发; 危险因素
Keywords:
Pituitary adenoma;  Postoperative recurrence;  Risk factors
分类号:
R 739.41; R 651.1+1
DOI:
10.13798/j.issn.1009-153X.2020.07.007
文献标志码:
A
摘要:
目的 探讨垂体腺瘤术后复发的危险因素。方法 回顾性分析2015年8月至2017年8月手术治疗的121例垂体腺瘤的临床资料。平均随访（19.59±15.57）月。复发的定义：术后复查MRI再次发现肿瘤或已降低的生化指标再次升高；或者术后残余肿瘤MRI复查示连续3个序列肿瘤直径超过2 mm。结果 121例中，术后复发20例，复发率为16.52%。单因素分析结果显示，年龄、肿瘤最大径、肿瘤侵袭、肿瘤增殖、肿瘤切除程度与垂体腺瘤术后复发有关（P<0.05）。多因素logistic回归分析结果显示，肿瘤侵袭性生长是垂体腺瘤术后复发的独立危险因素（P<0.05）。结论 肿瘤侵袭性生长是垂体腺瘤术后复发的独立危险因素，年轻病人需要延长术后随访期限
Abstract:
Objective To analyze the risk factors for postoperative recurrence of pituitary adenomas. Methods The clinical data of 121 patients with pituitary adenoma who underwent surgery from August 2015 to August 2017 were analyzed retrospectively. The mean follow-up was (19.59±15.57) months. The diagnostic criteria of tumor recurrence included: the re-examination of MRI after the operation showed pituitary adenomas in the patients who received total resection of tumor, or the diameter of tumor was more than 2 mm in 3 consecutive sequences in the patients with residual tumor after the operation. Results Of 121 patients, tumor recurrence occurred in 20 patients (16.52%). The univariate analysis showed that the age, the volume and maximum diameter of tumor, the tumor invasion, the tumor proliferation rate, and extent of tumor resection were related to the tumor recurrence (P<0.05). Multivariate logistic regression analysis showed that tumor invasion was an independent risk factor for postoperative recurrence of pituitary adenoma (P<0.05). Conclusion Tumor invasive growth is an independent risk factor for recurrence pituitary adenomas. Young patients need to prolong the postoperative follow-up period

参考文献/References:

[1] Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review [J]. Cancer, 2004, 101(3): 613-619.
[2] Sansur CA, Oldfield EH. Pituitary carcinoma [J]. Semin Oncol, 2010, 37(6): 591-593.
[3] Ko CC, Chen TY, Lim SW, et al. Prediction of recurrence in solid nonfunctioning pituitary macroadenomas: additional benefits of diffusion-weighted MR imaging [J]. J Neurosurg, 2019, 1(2): 1-9.
[4] Taghvaei M, Sadrehosseini SM, Ardakani JB, et al. Endo- scopic endonasal approach to the growth hormone-secreting pituitary adenomas: endocrinologic outcome in 68 patients [J]. World Neurosurg, 2018, 117(9): e259-e268.
[5] Lv L, Yin S, Zhou P, et al. Clinical and pathologic charac- teristics predicted the postoperative recurrence and progre- ssion of pituitary adenoma: a retrospective study with 10 years follow-up [J]. World Neurosurg, 2018, 118(10): e428- e435.
[6] 中国垂体腺瘤协作组，中华医学会神经外科学分会. 中国 复发性垂体腺瘤诊治专家共识（2019）[J]. 中华医学杂 志，2019，99（19）：1449-1453.
[7] Colin P, Jovenin N, Delemer B, et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a pros- pective study of 110 patients [J]. Int J Radiat Oncol Biol Phys, 2005, 62(2): 333-341.
[8] Kuo CH, Yen YS, Wu JC, et al. Primary endoscopic transna- sal transsphenoidal surgery for giant pituitary adenoma [J]. World Neurosurg, 2016, 91: 121-128.
[9] 李　宁，许新堂，李爱民，等. 巨大垂体腺瘤开颅手术治疗 体会[J]. 中国临床神经外科杂志，2014，19（4）：235-236.
[10] Castano-Leon AM, Paredes I, Munarriz PM, et al. Endo- scopic transnasal trans-sphenoidal approach for pituitary adenomas: a comparison to the microscopic approach cohort by propensity score analysis [J]. Neurosurgry, 2019, 7(6): 1- 9.
[11] 薛亚军，赵耀东，崔大明，等. 内镜下经鼻蝶窦手术治疗 复发或再生长垂体腺瘤疗效分析[J]. 中华医学杂志， 2015，95（5）：334-338.
[12] Bodhinayake I, Ottenhausen M, Mooney M A, et al. Results and risk factors for recurrence following endoscopic endo- nasal transsphenoidal surgery for pituitary adenoma [J]. Clin Neurol Neurosurg, 2014, 119(4): 75-79.
[13] Watts AK, Easwaran A, McNeill P, et al. Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: results from a single Australian centre [J]. Clin Endocrinol (Oxf), 2017, 87(3): 264-271.
[14] Daly AF., Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium [J]. J Clin Endocrinol Metab, 2006, 91 (12): 4769-4775.
[15] Broersen LH, Haalen FM, Biermasz NR, et al. Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushing's disease: surgical outcome, mortality, and complications [J]. Orphanet J Rare Dis, 2019, 14(1): 64-72.
[16] Babu H, Ortega A, Nuno M, et al. Long-term endocrine out- comes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors [J]. Neurosurgery, 2017, 81(2): 357-366.
[17] Trouillas J, Roy P, Sturm N, et al. A new prognostic clinico- pathological classification of pituitary adenomas: a multi- centric case-control study of 410 patients with 8 years post- operative follow-up [J]. Acta Neuropathol, 2013, 126(1): 123-135.
[18] 李储忠，张亚卓. 2017版WHO垂体肿瘤分类解读[J]. 中 华神经外科杂志，2018，34（1）：1-5.

相似文献/References:

[1]余龙洋　李亚楠　周　宇　戴冬伟　曹依群　岳志健.垂体腺瘤经蝶术后并发蛛网膜下腔出血的临床分析 （附6例报道）[J].中国临床神经外科杂志,2016,(06):372.[doi:10.13798/j.issn.1009-153X.2016.06.018]
[2]王国良　高　寒　张小鹏　公方和　李天栋.89例垂体腺瘤的手术治疗体会[J].中国临床神经外科杂志,2016,(07):435.[doi:10.13798/j.issn.1009-153X.2016.07.016]
[3]王亚平　贾晓雄　王　珺　王林林　谭溢涛　马德得　夏鹤春.神经内镜下与显微镜下经鼻蝶入路手术切除垂体腺瘤的疗效对比分析[J].中国临床神经外科杂志,2016,(03):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
　WANG Ya-ping,JIA Xiao-xiong,WANG-Jun,et al.Resection of pituitary adenomas by endoscopic and microscopic surgery via transnasal transsphenoidal approach: a comparative analysis[J].,2016,(07):145.[doi:10.13798/j.issn.1009-153X.2016.03.004]
[4]张海红　马　磊　张　威　郭　康　衡立君　贾　栋.垂体腺瘤MRI特征与视觉功能损害的关系分析[J].中国临床神经外科杂志,2016,(01):27.[doi:10.13798/j.issn.1009-153X.2016.01.010]
　ZHANG Hai-hong,MA Lei,ZHANG Wei,et al.Analysis of MRI characteristics and visual function in patient with pituitary adenomas[J].,2016,(07):27.[doi:10.13798/j.issn.1009-153X.2016.01.010]
[5]王先祥　张义泉　李庆新　王　斌　 肖　瑾　张　科.经单鼻孔蝶窦入路神经内镜下切除垂体腺瘤[J].中国临床神经外科杂志,2015,(12):715.[doi:10.13798/j.issn.1009-153X.2015.12.004]
　WANG Xian-xiang,ZHANG Yi-quan,LI Qing-xin,et al.Endoscopic endonasal transsphenoidal surgery for pituitary adenomas[J].,2015,(07):715.[doi:10.13798/j.issn.1009-153X.2015.12.004]
[6]马　涛　徐　韬.经蝶入路内镜手术与显微手术治疗垂体腺瘤疗效的Meta分析[J].中国临床神经外科杂志,2015,(12):748.[doi:10.13798/j.issn.1009-153X.2015.12.015]
[7]雷　霆.注重基础训练和知识更新，不断提高垂体腺瘤诊疗水平[J].中国临床神经外科杂志,2015,(10):577.[doi:10.13798/j.issn.1009-153X.2015.10.001]
[8]闫　进　李　松　杨　辉.1H-MRS对卵泡刺激素免疫阳性垂体腺瘤的诊断和预后评估的价值[J].中国临床神经外科杂志,2015,(10):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
　YAN Jin,LI Song,YANG Hui..Value of 1H-MRS to diagnosis and assessment of prognoses in patients with non-functioning gonadotroph adenomas[J].,2015,(07):588.[doi:10.13798/j.issn.1009-153X.2015.10.004]
[9]夏为民　邵耐远　唐　科.神经内镜辅助经鼻蝶入路手术治疗急性垂体腺瘤卒中[J].中国临床神经外科杂志,2015,(07):437.[doi:10.13798/j.issn.1009-153X.2015.07.020]
[10]王齐齐　陈　俊　王焕明　胡　飞.脊索瘤合并垂体腺瘤1例[J].中国临床神经外科杂志,2015,(07):448.[doi:10.13798/j.issn.1009-153X.2015.07.025]
[11]罗志华　张严国　黄从刚　王春燕　李乾锋.lncRNA MEG3表达水平及甲基化状态与垂体腺瘤术后复发的关系[J].中国临床神经外科杂志,2020,(12):825.[doi:10.13798/j.issn.1009-153X.2020.12.003]
　LUO Zhi-hua,ZHANG Yan-guo,HUANG Cong-gang,et al.Relationship between expression level and methylation status of lncRNA MEG3 and postoperative recurrence of pituitary adenoma[J].,2020,(07):825.[doi:10.13798/j.issn.1009-153X.2020.12.003]
[12]曾坚锋　李　钢　刘仲海等.垂体腺瘤组织lncRNA-POU3F3表达水平与术后复发的关系[J].中国临床神经外科杂志,2021,26(03):168.[doi:10.13798/j.issn.1009-153X.2021.03.008]
　ZENG Jian-feng,LI Gang,LIU Zhong-hai,et al.Relationship between expression level of lncRNA-POU3F3 in pituitary adenoma tissues and postoperative recurrence of patients with pituitary adenoma[J].,2021,26(07):168.[doi:10.13798/j.issn.1009-153X.2021.03.008]
[13]聂兴玉,张铁耀,郝昌.垂体腺瘤组织miR-26b-5p表达与术后复发的关系[J].中国临床神经外科杂志,2022,27(06):458.[doi:10.13798/j.issn.1009-153X.2022.06.008]
　NIE Xing-yu,ZHANG Tie-yao,HAO Chang.Expression of miR-26b-5p in pituitary adenoma tissues and its relationship with postoperative recurrence[J].,2022,27(07):458.[doi:10.13798/j.issn.1009-153X.2022.06.008]

备注/Memo

备注/Memo:
（2019-10-29收稿，2019-12-04修回）通讯作者：张溢华，E-mail：89560032@qq.com
更新日期/Last Update: 2020-07-20